tiprankstipranks
Trending News
More News >
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
US Market
Advertisement

Scholar Rock Holding (SRRK) Stock Forecast & Price Target

Compare
483 Followers
See the Price Targets and Ratings of:

SRRK Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Scholar
Rock Holding
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SRRK Stock 12 Month Forecast

Average Price Target

$47.50
▲(27.55% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Scholar Rock Holding in the last 3 months. The average price target is $47.50 with a high forecast of $53.00 and a low forecast of $44.00. The average price target represents a 27.55% change from the last price of $37.24.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","18":"$18","30":"$30","42":"$42","54":"$54"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$53.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,18,30,42,54],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.12,34.64923076923077,36.178461538461534,37.707692307692305,39.23692307692308,40.76615384615384,42.29538461538461,43.824615384615385,45.35384615384615,46.88307692307692,48.41230769230769,49.94153846153846,51.47076923076923,{"y":53,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.12,34.22615384615384,35.33230769230769,36.43846153846154,37.54461538461538,38.65076923076923,39.75692307692307,40.86307692307692,41.96923076923077,43.075384615384614,44.18153846153846,45.28769230769231,46.393846153846155,{"y":47.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.12,33.956923076923076,34.793846153846154,35.63076923076923,36.4676923076923,37.30461538461538,38.14153846153846,38.97846153846154,39.815384615384616,40.652307692307694,41.48923076923077,42.326153846153844,43.16307692307692,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.42,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.06,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$53.00Average Price Target$47.50Lowest Price Target$44.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on SRRK
Leerink Partners
Leerink Partners
$51$48
Buy
28.89%
Upside
Reiterated
09/25/25
Leerink Partners Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)Leerink Partners analyst Mani Foroohar lowered the price target on Scholar Rock (NASDAQ: SRRK) to $48.00 (from $51.00) while maintaining a Outperform rating.
Piper Sandler Analyst forecast on SRRK
Piper Sandler
Piper Sandler
$52$51
Buy
36.95%
Upside
Reiterated
09/24/25
Scholar Rock price target lowered to $51 from $52 at Piper SandlerScholar Rock price target lowered to $51 from $52 at Piper Sandler
Truist Financial Analyst forecast on SRRK
Truist Financial
Truist Financial
Buy
Reiterated
09/24/25
Truist Financial Sticks to Their Buy Rating for Scholar Rock Holding (SRRK)
Barclays Analyst forecast on SRRK
Barclays
Barclays
$45$44
Buy
18.15%
Upside
Reiterated
09/23/25
Scholar Rock Holding (SRRK) Receives a Buy from Barclays
J.P. Morgan Analyst forecast on SRRK
J.P. Morgan
J.P. Morgan
Buy
Reiterated
09/23/25
Optimistic Outlook for Scholar Rock Holdings Amid Regulatory Challenges
TD Cowen Analyst forecast on SRRK
TD Cowen
TD Cowen
Buy
Reiterated
09/23/25
Scholar Rock Holding (SRRK) Gets a Buy from TD Cowen
H.C. Wainwright Analyst forecast on SRRK
H.C. Wainwright
H.C. Wainwright
$50$44
Buy
18.15%
Upside
Reiterated
09/23/25
Buy Rating for Scholar Rock Holding: Clinical Promise and Financial Stability Amid Manufacturing DelayValuation and risks to achievement of price target. Given the recently announced CRL we have adjusted our timelines for apitegromab’s launch to start in late 2026 (previously 2025). Hence, our new 12-month price target of $44 (down from $50) is based on an equally weighted composite of (a) $46.83/share, as a 30x multiple of taxed and diluted FY34 GAAP EPS of $3.99 discounted at 11%, and (b) an NPV of $41.5/share (discount rate 11.0%, growth rate 2.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development-stage biopharmaceutical company.
BMO Capital Analyst forecast on SRRK
BMO Capital
BMO Capital
$45
Buy
20.84%
Upside
Reiterated
09/19/25
Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Akero Therapeutics (AKRO)We remain confident in the upside potential of SRRK shares despite potential minor delays in apitegromab's PDUFA, and we reiterate our Outperform rating.
Roth MKM Analyst forecast on SRRK
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$45
Buy
20.84%
Upside
Initiated
09/17/25
Scholar Rock Holding (SRRK) Receives a New Rating from Roth MKMSRRK Initiated Overweight w/$45.00 PT at Barclays
Jefferies Analyst forecast on SRRK
Jefferies
Jefferies
$50
Buy
34.26%
Upside
Initiated
08/21/25
Scholar Rock assumed with a Buy at JefferiesScholar Rock assumed with a Buy at Jefferies
Raymond James Analyst forecast on SRRK
Raymond James
Raymond James
$53
Buy
42.32%
Upside
Reiterated
08/06/25
Scholar Rock Holding (SRRK) Receives a Buy from Raymond James
Cantor Fitzgerald Analyst forecast on SRRK
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
07/17/25
Scholar Rock initiated with an Overweight at Cantor FitzgeraldScholar Rock initiated with an Overweight at Cantor Fitzgerald
LifeSci Capital Analyst forecast on SRRK
LifeSci Capital
LifeSci Capital
$48
Buy
28.89%
Upside
Reiterated
06/18/25
Scholar Rock's Strategic Shift and Promising Advancements Drive Buy Rating
Wedbush
$50
Buy
34.26%
Upside
Initiated
03/17/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on SRRK
Leerink Partners
Leerink Partners
$51$48
Buy
28.89%
Upside
Reiterated
09/25/25
Leerink Partners Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)Leerink Partners analyst Mani Foroohar lowered the price target on Scholar Rock (NASDAQ: SRRK) to $48.00 (from $51.00) while maintaining a Outperform rating.
Piper Sandler Analyst forecast on SRRK
Piper Sandler
Piper Sandler
$52$51
Buy
36.95%
Upside
Reiterated
09/24/25
Scholar Rock price target lowered to $51 from $52 at Piper SandlerScholar Rock price target lowered to $51 from $52 at Piper Sandler
Truist Financial Analyst forecast on SRRK
Truist Financial
Truist Financial
Buy
Reiterated
09/24/25
Truist Financial Sticks to Their Buy Rating for Scholar Rock Holding (SRRK)
Barclays Analyst forecast on SRRK
Barclays
Barclays
$45$44
Buy
18.15%
Upside
Reiterated
09/23/25
Scholar Rock Holding (SRRK) Receives a Buy from Barclays
J.P. Morgan Analyst forecast on SRRK
J.P. Morgan
J.P. Morgan
Buy
Reiterated
09/23/25
Optimistic Outlook for Scholar Rock Holdings Amid Regulatory Challenges
TD Cowen Analyst forecast on SRRK
TD Cowen
TD Cowen
Buy
Reiterated
09/23/25
Scholar Rock Holding (SRRK) Gets a Buy from TD Cowen
H.C. Wainwright Analyst forecast on SRRK
H.C. Wainwright
H.C. Wainwright
$50$44
Buy
18.15%
Upside
Reiterated
09/23/25
Buy Rating for Scholar Rock Holding: Clinical Promise and Financial Stability Amid Manufacturing DelayValuation and risks to achievement of price target. Given the recently announced CRL we have adjusted our timelines for apitegromab’s launch to start in late 2026 (previously 2025). Hence, our new 12-month price target of $44 (down from $50) is based on an equally weighted composite of (a) $46.83/share, as a 30x multiple of taxed and diluted FY34 GAAP EPS of $3.99 discounted at 11%, and (b) an NPV of $41.5/share (discount rate 11.0%, growth rate 2.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development-stage biopharmaceutical company.
BMO Capital Analyst forecast on SRRK
BMO Capital
BMO Capital
$45
Buy
20.84%
Upside
Reiterated
09/19/25
Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Akero Therapeutics (AKRO)We remain confident in the upside potential of SRRK shares despite potential minor delays in apitegromab's PDUFA, and we reiterate our Outperform rating.
Roth MKM Analyst forecast on SRRK
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$45
Buy
20.84%
Upside
Initiated
09/17/25
Scholar Rock Holding (SRRK) Receives a New Rating from Roth MKMSRRK Initiated Overweight w/$45.00 PT at Barclays
Jefferies Analyst forecast on SRRK
Jefferies
Jefferies
$50
Buy
34.26%
Upside
Initiated
08/21/25
Scholar Rock assumed with a Buy at JefferiesScholar Rock assumed with a Buy at Jefferies
Raymond James Analyst forecast on SRRK
Raymond James
Raymond James
$53
Buy
42.32%
Upside
Reiterated
08/06/25
Scholar Rock Holding (SRRK) Receives a Buy from Raymond James
Cantor Fitzgerald Analyst forecast on SRRK
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiated
07/17/25
Scholar Rock initiated with an Overweight at Cantor FitzgeraldScholar Rock initiated with an Overweight at Cantor Fitzgerald
LifeSci Capital Analyst forecast on SRRK
LifeSci Capital
LifeSci Capital
$48
Buy
28.89%
Upside
Reiterated
06/18/25
Scholar Rock's Strategic Shift and Promising Advancements Drive Buy Rating
Wedbush
$50
Buy
34.26%
Upside
Initiated
03/17/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Scholar Rock Holding

1 Month
xxx
Success Rate
5/8 ratings generated profit
63%
Average Return
+2.80%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +2.80% per trade.
3 Months
xxx
Success Rate
7/10 ratings generated profit
70%
Average Return
+61.93%
initiated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +61.93% per trade.
1 Year
Etzer DaroutBarclays
Success Rate
7/8 ratings generated profit
88%
Average Return
+134.44%
reiterated a buy rating 9 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +134.44% per trade.
2 Years
xxx
Success Rate
7/8 ratings generated profit
88%
Average Return
+190.28%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +190.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRRK Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
6
10
8
5
3
Buy
8
10
11
15
19
Hold
6
3
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
23
19
20
22
In the current month, SRRK has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SRRK average Analyst price target in the past 3 months is 47.50.
Each month's total comprises the sum of three months' worth of ratings.

SRRK Financial Forecast

SRRK Earnings Forecast

Next quarter’s earnings estimate for SRRK is -$0.84 with a range of -$1.03 to -$0.67. The previous quarter’s EPS was -$0.98. SRRK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year SRRK has Preformed in-line its overall industry.
Next quarter’s earnings estimate for SRRK is -$0.84 with a range of -$1.03 to -$0.67. The previous quarter’s EPS was -$0.98. SRRK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year SRRK has Preformed in-line its overall industry.

SRRK Sales Forecast

Next quarter’s sales forecast for SRRK is $62.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $0.00. SRRK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year SRRK has Preformed in-line its overall industry.
Next quarter’s sales forecast for SRRK is $62.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $0.00. SRRK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year SRRK has Preformed in-line its overall industry.

SRRK Stock Forecast FAQ

What is SRRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Scholar Rock Holding Corp’s 12-month average price target is 47.50.
    What is SRRK’s upside potential, based on the analysts’ average price target?
    Scholar Rock Holding Corp has 27.55% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SRRK a Buy, Sell or Hold?
          Scholar Rock Holding Corp has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Scholar Rock Holding Corp’s price target?
            The average price target for Scholar Rock Holding Corp is 47.50. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $53.00 ,the lowest forecast is $44.00. The average price target represents 27.55% Increase from the current price of $37.24.
              What do analysts say about Scholar Rock Holding Corp?
              Scholar Rock Holding Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of SRRK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis